Systemic lupus erythematosus: Demographics, prognosis, and outcome

Journal of Rheumatology

Volumn 24, Issue SUPPL. 48, 1997, Pages 67-71

  Klippel, John H ^a,b  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Demographics; Prognosis; Systemic lupus erythematosus

Indexed keywords

ANTIMALARIAL AGENT; CORTICOSTEROID; NONSTEROID ANTIINFLAMMATORY AGENT; ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLYCOPROTEIN GP 39; GONADORELIN AGONIST; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; OLIGODEOXYNUCLEOTIDE; PRASTERONE; VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; CHILD; DRUG COMBINATION; FEMALE; HUMAN; INCIDENCE; MALE; PATHOPHYSIOLOGY; PRESCHOOL CHILD; PROGNOSIS; REVIEW; RISK FACTOR; SEX RATIO; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; UNITED STATES; BONE NECROSIS; CANCER; CARDIOTOXICITY; CONFERENCE PAPER; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MENTAL DISEASE; NEUROLOGIC DISEASE; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; REPRODUCTIVE TOXICITY;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGE DISTRIBUTION; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INCIDENCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PROGNOSIS; RISK FACTORS; SEX DISTRIBUTION; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 0030972737     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Mills JA: Systemic lupus erythematosus. N Engl J Med 1994;330:1871-9.
2. Boumpas DT, Austin HA, Fessier BJ, Balow JE, Klippel JH, Lockshin MD: Systemic lupus erythematosus: Emerging concepts. I. Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med 1995;122:940-50.
3. Boumpas DT, Fessler BJ, Austin HA, Balow JE, Klippel JH, Lockshin MD: Systemic lupus erythematosus: Emerging concepts. II. Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med 1995;123:42-53.
4. West SG, Emlen W, Wener MH, Kotzin BL: Neuropsychiatric lupus erythematosus: A 10-year prospective study on the value of diagnostic tests. Am J Med 1995;99:153-63.
5. Hirsch R, White P: Systemic lupus in children. Current Pediatrics 1991;1:85-8.
6. Donadio JV Jr, Hart GM, Bergstralh EJ, Holley KE: Prognostic determinants in lupus nephritis: A long-term clinicopathologic study. Lupus 1995;4:109-15.
7. Austin HA, Boumpas DT, Vaughan EM, Balow JE: Predicting renal outcomes in severe lupus nephritis: Contributions of clinical and histologic data. Kidney Int 1994;45:544-50.
8. Boumpas DT, Austin HA, Vaughan EM, et al: Severe lupus nephritis: Controlled trial of pulse methylprednisolone versus two different regimens of pulse cyclophosphamide. Lancet 1992;340-741-4.
9. Neuwelt CM, Lacks S, Kaye BR, et al: Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 1995;98:32-41.
10. Euler HH, Schroeder JO, Harten P, et al: Treatment-free remission in severe lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis Rheum 1994;37:1784-94.
11. Lupus Plasmapheresis Study Group: Plasmapheresis and subsequent pulse cyclophosphamide versus pulse cyclophosphamide alone in severe lupus: Design of the LPSG trial. J Clin Apheresis 1991;6:40-1.
12. Radhakrishnan J, Kunis CL, D'Agati V, et al: Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 1994;42:147-54.
13. Tokuda M, Kurata N, Mizoguchi A, et al: Effect of low-dose cyclosporin A on systemic lupus erythematosus. Arthritis Rheum 1994;37:551-8.
14. Waltz LeBlanc BA, Dagenais P, Urowitz MB, et al: Methotrexate in systemic lupus erythematosus. J Rheumatol 1994;21:836-8.
15. Galarza D, Esquivel J, Villarreal M, et al: Methotrexate in lupus nephritis: An uncontrolled study, preliminary results (abstr). Arthritis Rheum 1991;(suppl)34:S187.
16. Scott D, Balow J, Austin H, et al: A pilot study of cladrabine (2′ chlorodeoxyadenosine) in lupus nephritis (abstr). Arthritis Rheum 1995;(suppl)38:S304.
17. McMurray RW, Weidensaul D, Allen SH, Walker SE: Efficacy of bromocriptine in an open-label therapeutic trial for systemic lupus erythematosus (abstr). Lupus 1995;4:66.
18. ® depot) in the treatment of lupus patients (abstr). Arthritis Rheum 1993;(suppl)36:S227.
19. van Vollenhoven RF, Engleman EG, McGuire JL: Dehydrocpiandrosterone in systemic lupus erythematosus: Results of a double-blinded, placebo-controlled, randomized clinical trial. Anhritis Rheum 1995;38:1826-31.
20. Finck BK, Linsley PS, Wofsy D: Treatment of murine lupus with CTLA4Ig. Science 1994;265:1225-7.
21. Burns C, Early G, Laman J, et al: Anti-CD40 ligand antibody treatment of NZB/NZW murine lupus-like nephritis (abstr). Arthritis Rheum 1994;(suppl)37:S390.
22. Raz E, Dudler J, Lotz M, et al: Modulation of disease activity in murine systemic lupus erythematosus by cytokine gene delivery. Lupus 1995;4:286-92.
23. Lee ML, Spertini F, Leimgruber A, et al: Updated phase I clinical results with an idiotypic vaccine (3E10) for systemic lupus erythematosus (abstr). Arthritis Rheum 1995;(suppl)38:S303.
24. Weisman MH, Bluestein HG, Berner CM, de Haan HA: Reduction in circulating dsDNA antibody titer after administration of LJP 394. J Rheumatol 1997;24:314-8.
25. Gladman DD: Prognosis and treatment of systemic lupus erythematosus. Curr Opin Rheumatol 1995;7:402-8,
26. Esdaile JM, Abrahamowicz M, Joseph L, MacKenzie T, Li Y, Danoff D: Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus: Why some tests fail. Arthritis Rheum 1996;39:370-8.
27. Suzuki N, Harada T, Mizushima Y, Sakane T: Possible pathogenic role of cationic antiDNA autoantibodies in the development of nephritis in patients with systemic lupus erythematosus. J Immunol 1993;151:1128-36.
28. Harada T, Suzuki N, Mizushima Y, Sakane T: Usage of a novel germ-line Ig variable gene for cationic anti-DNA autoantibodies in human lupus nephritis and its role for the development of the disease. J Immunol 1994;153:4806-15.
29. Howard TW, Iannini MJ, Burge JJ, Davis JS: Rheumatoid factor, cryoglobulinemia, anti-DNA, and renal disease in patients with systemic lupus erythematosus. J Rheumatol 1991;18:826-30.
30. McCarty GA, Harley JB, Reichlin M: A distinctive autoantibody profile in black female patients with lupus nephritis. Arthritis Rheum 1993;36:1560-5.
31. Drake CG, Rozzo SJ, Hirschfeld HF, Smarnworawong NP, Palmer E, Kotzin BL: Analysis of the New Zealand Black contribution to lupus-like renal disease. Multiple genes that operate in a threshold manner. J Immunol 1995;154:2441-7.
32. Fronek Z, Timmerman LA, Alper CA, et al: Major histocompatibility complex genes and susceptibility to systemic lupus erythematosus. Arthritis Rheum 1990;33:1542-53.
33. Salmon JE, Millard S, Schachter L, et al: FcIIA alleles are heritable risk factors for lupus nephritis in African-Americans (abstr). Arthritis Rheum 1995;(suppl)38:S398.
34. Pistiner M, Wallace DJ, Nessim S, Metzger AL. Klinenberg JR: Lupus erythematosus in the 1980s: A survey of 570 patients. Semin Arthritis Rheum 1991;21:55-64.
35. Ward MM, Pyun E, Studenski S: Long-term survival in systemic lupus erythematosus: Patient characteristics associated with poorer outcomes. Arthritis Rheum 1995;38:274-83.
36. Abu-Shakra M, Urowitz MB, Gladman DD: Improved survival in a cohort of SLE patients compared to the general population over a 25-year period of observation (abstr). Arthritis Rheum 1994;(suppl)37:S216.
37. Massardo L, Martinez ME, Jacobelli S, Villarroel L, Rosenberg H, Rivero S: Survival of Chilean patients with systemic lupus erythematosus. Semin Arthritis Rheum 1994;24:1-11.
38. Platt JL, Burke BA, Fish AJ, Kim Y, Michael AF: Systemic lupus erythematosus in the first two decades of life. Am J Kidney Dis 1982;(suppl 1)2:212-21.
39. Glidden RS, Mantzouranis EC, Borel Y: Systemic lupus erythematosus in childhood: Clinical manifestations and improved survival in fifty-five patients. Clin Immunol Immunopathol 1983;29:196-210.
40. Levy M, Montes de Oca M, Claude-Babron M: Unfavorable outcomes (end-stage renal failure/death) in childhood onset systemic lupus erythematosus. A multicenter study in Paris and its environs. Clin Exp Rheumatol 1994;(suppl 10)12:S63-S68.
41. Cameron JS: Lupus and lupus nephritis in children. Adv Nephrol 1993;2:59-119.
42. Cohen MG, Li EK: Mortality in systemic lupus erythematosus: Active disease is the most important factor. Aust NZJ Med 1992;22:5-8.
43. Sturfelt G, Eskilsson J, Nived O, Truedsson L, Valind S: Cardiovascular disease in systemic lupus erythematosus. A study of 75 patients from a defined population. Medicine 1992;71:216-23.
44. Hahn BH: The potential role of autologous stem cell transplantation in patients with systemic lupus erythematosus. J Rheumatol 1997;(suppl 48)24:89-93.